[Efficacy and safety of patients immunization with chronic obstructive pulmonary disease with monoclonal antibodies].
V N AntonovG L IgnatovaPublished in: Terapevticheskii arkhiv (2023)
The effectiveness of pre-contact prevention of COVID-19 was 88.8%. The administration of the drug does not provoke an exacerbation of the underlying disease. The main clinical and functional indicators have positive dynamics by the 6th month of follow-up. The drug is well tolerated and has no significant both early and late complications.
Keyphrases
- chronic obstructive pulmonary disease
- end stage renal disease
- coronavirus disease
- newly diagnosed
- sars cov
- ejection fraction
- randomized controlled trial
- chronic kidney disease
- peritoneal dialysis
- systematic review
- prognostic factors
- risk factors
- patient reported outcomes
- respiratory syndrome coronavirus
- extracorporeal membrane oxygenation